Regulatory China’s NMPA approves Akeso’s gumokimab for plaque psoriasis Pharmaceutical Business ReviewThe approval is based on data from one pivotal Phase III trial (AK111-301) and three additional supportive studies.Immunology & InflammationRead full story pharminent June 12, 2026 (Last updated: June 19, 2026) Pharmaceutical Business Review The approval is based on data from one pivotal Phase III trial (AK111-301) and three additional supportive studies. Immunology & Inflammation Read full story Post navigation Previous: How Medicare Advantage Rebates Disadvantage Medicare’s Stand-Alone Drug Plan MarketNext: Novo Nordisk comeback stirs as Wegovy pill wins UK approval Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026